Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Aurovertin B derivative and its preparation method and application

A derivative, AUB-1 technology, applied in the field of medicine, can solve the problems of insufficient activity and specificity of triple-negative breast cancer, and achieve the effect of improving druggability, excellent drug efficacy and activity, and good application prospects

Active Publication Date: 2021-08-24
ZHEJIANG UNIV OF TECH
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] In order to overcome the deficiencies in the activity and specificity of existing drugs in the treatment of triple negative breast cancer, the present invention provides a preparation method of aurovertin B derivatives and aurovertin B derivatives, and the use of aurovertin B derivatives in the preparation of triple negative breast cancer Use of Drugs in Breast Cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Aurovertin B derivative and its preparation method and application
  • Aurovertin B derivative and its preparation method and application
  • Aurovertin B derivative and its preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0045] Embodiment 1: the synthesis of compound described in formula II

[0046] Weigh 4.75g (0.028mol) of phenylthioacetic acid into a round bottom flask, add 30ml of acetic acid, stir on a stirrer until completely dissolved, slowly add 30% H 2 o 2 7ml (0.069 mol), the ice bath was removed after feeding, and the reaction was stirred at room temperature for 3 hours, and the progress of the reaction was detected by pointing a plate during the process. After the reaction of the raw materials is complete, slowly add 12.5ml (0.300 mol) of fuming nitric acid under the condition of ice bath at 0°C, and reflux at 110°C for 2 hours. Needle-like crystals were precipitated, filtered, and the filtered solid was washed three times with a small amount of water, and vacuum-dried to obtain the target product, a total of 2.29 g. The yield was 44.3% based on the amount of phenylthioacetic acid.

Embodiment 2

[0047] Example 2: Synthesis of aurovertin B derivative AUB-1 (the synthetic route is shown in formula 1)

[0048]

[0049] Weigh the compound described in Formula II (144 mg, 0.39 mmol) into a round bottom flask, add 4 mL of THF, select a moderate stirring magnet, stir on a stirrer to dissolve it, then add 0.4 mL of NaOH aqueous solution (36.8 mg, 0.92 mmol ), and added 1,4-butanediol (0.63mmol), and reacted at room temperature for 3h. During the process, TLC monitored the reaction process. After the raw materials were completely converted, 4mL of distilled water was added to complete the reaction. The reaction solution was extracted three times with 5mL of ethyl acetate. After liquid separation, the organic layer was taken and spin-dried, and separated by silica gel column chromatography (200 mesh-300 mesh), the eluent was petroleum ether: acetone = 3.5:1, and a thin layer of silica gel was used for detection. The eluate with strong ultraviolet absorption spots under the l...

Embodiment 3

[0053] Example 3: Synthesis of aurovertin B derivative AUB-2 (the synthetic route is shown in Formula 1)

[0054]

[0055] Weigh the compound described in Formula II (144 mg, 0.39 mmol) into a round bottom flask, add 4 mL of THF, select a moderate stirring magnet, stir on a stirrer to dissolve it, then add 0.4 mL of NaOH aqueous solution (36.8 mg, 0.92 mmol ), and added 1,5-pentanediol (0.63mmol), and reacted at room temperature for 3h. During the process, TLC monitored the reaction process. After the raw materials were completely converted, 4mL of distilled water was added to complete the reaction. The reaction solution was extracted three times with 5mL of ethyl acetate. After liquid separation, the organic layer was taken and spin-dried, and separated by silica gel column chromatography (200 mesh-300 mesh), the eluent was petroleum ether: acetone = 3.5:1, and a thin layer of silica gel was used for detection. The eluate with strong ultraviolet absorption spots under the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an aurovertin B derivative, a preparation method of the aurovertin B derivative, and an application of the aurovertin B derivative in preparing a medicine for treating triple-negative breast cancer. The polarity of the aurovertin B derivatives of the present invention is significantly improved, which is conducive to the improvement of preparations and bioavailability in vivo; it has better druggability; in addition, compared with aurovertin B, the aurovertin B derivatives of the present invention, The activity of the compound is improved, the toxicity to normal cells is reduced, and the druggability thereof is improved. Therefore, the aurovertin B derivatives have excellent application prospects in the preparation of drugs for treating triple-negative breast cancer, especially when the triple-negative breast cancer cells are HCC1937 cells and MDA-MB-231 cells, the drug activity is excellent.

Description

[0001] (1) Technical field [0002] The invention belongs to the technical field of medicine, and relates to aurovertin B derivatives, a preparation method of aurovertin B derivatives, and the application of aurovertin B derivatives in preparing medicines for treating triple-negative breast cancer. [0003] (2) Background technology [0004] Breast cancer is the most common disease among women's cancers, accounting for 23% of the cancer incidence, and the number of deaths from the disease is as high as 400,000 people every year. Triple-negative breast cancer (TNBC) is a subtype of breast cancer defined by immunohistochemistry as the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 genes Express. Although patients with triple-negative breast cancer account for only 15%-20% of all breast cancer patients, their 5-year survival rate is significantly lower than that of other breast cancer subtypes. TNBC is a heterogeneous tumor char...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D493/08A61P35/00
CPCA61P35/00C07D493/08
Inventor 占扎君吴杰非马列峰吴睿单伟光
Owner ZHEJIANG UNIV OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com